| Name | JH-VIII-157-02 |
| Description | JH-VIII-157-02 is an inhibitor of ALK and inhibits echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) with IC50s of 2 nM for EML4-ALK G1202R, EML4-ALKwt, EML4-ALK C1156Y, EML4-ALK F1174L, and EML4-ALK F1174L. |
| In vitro | JH-VIII-157-02 potently inhibits EML4-ALKS1206Y, EML4-ALKG1269A, EML4-ALKL1196M, EML4-ALK1151Tins, and EML4-ALKL1152R with IC50s of 2, 3, 58, 107 and 196 nM, respectively. JH-VIII-157-02 has selectivity at other kinases, including IRAK1, CLK4, RET, RET V804L, RET V804M and IRAK 4 with IC50s of 14 nM, 14 nM, 3 nM, 13 nM, 12 nM, and 465 nM, respectively[1]. |
| In vivo | In mice, JH-VIII-157-02 (10 mg/kg) exhibits good oral bioavailability and penetrates the central nervous system[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 25 mg/mL (53.7 mM), Sonication is recommended.
|
| Keywords | MicrotubuleAssociated | Microtubule Associated | JH-VIII-157-02 | JHVIII15702 | JH VIII 157 02 | Inhibitor | inhibit | EML4-ALKwt, cell assay | EML4-ALK G1202R, cell assay | EML4-ALK F1174L, cell assay | EML4-ALK C1156Y, cell assay | Cluster of differentiation 246 | CD246 | Anaplastic lymphoma kinase (ALK) | Anaplastic lymphoma kinase | ALK tyrosine kinase receptor | ALK |
| Inhibitors Related | Flubendazole | SB-431542 | N-Phenylbenzylamine | Mebendazole | 4-Isopropoxybenzoic acid | Pregnenolone acetate | Crizotinib | α-Cyclodextrin | Brigatinib | Methylene Blue trihydrate | 4'-Demethylepipodophyllotoxin | Albendazole |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Microtubule-Targeted Compound Library | Angiogenesis related Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Cytoskeletal Signaling Pathway Compound Library | Anti-Cancer Compound Library |